|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CH02
|
|
gptkbp:bioavailability
|
1.8%
|
|
gptkbp:brand
|
gptkb:Rozerem
|
|
gptkbp:CASNumber
|
196597-26-9
|
|
gptkbp:compatibleWith
|
controlled substance (US)
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developer
|
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:drugClass
|
melatonin receptor agonist
|
|
gptkbp:eliminationHalfLife
|
1-2.6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C16H21NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ramelteon
|
|
gptkbp:interactsWith
|
gptkb:fluvoxamine
gptkb:rifampin
gptkb:ketoconazole
|
|
gptkbp:IUPACName
|
(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
MT1 and MT2 melatonin receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
259.34 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
82%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
somnolence
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Rozerem
gptkb:MT2_receptor
gptkb:melatonin_receptors
|
|
gptkbp:bfsLayer
|
7
|